Pancreatic Cancer Research

ResearcherUniversity of North Carolina at Chapel HillActive in the last 2 years

Hana Algül

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-5067-7031; OpenAlex author ID A5011006455. Sources: OpenAlex.

Their work

Papers
59 (first author 6, last author 13)
Trials
0
Grants
0
Labs led
1
Collaborators
250
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 3 papers · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: 3 papers · 2018: 3 papers · 2019: 8 papers · 2020: 9 papers · 2021: 5 papers · 2022: 4 papers · 2023: 3 papers · 2024: 6 papers · 2025: 4 papers · 2026: 4 papers

Papers 50 of 59

  1. The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol. Co-author DOI 10.1002/gin2.70074↗
  2. Pancreatic ductal adenocarcinoma: The Vision of Heracles. Co-author DOI 10.1016/j.ccell.2026.07.014↗
  3. Growth differentiation factor-15 (GDF-15) in localized pancreatic adenocarcinoma treated with multiagent chemotherapy: a biomarker analysis from the NEOLAP tri… Co-author DOI 10.1016/j.esmogo.2025.100274↗
  4. LSD1-GLS2 axis drives subtype-specific chemoresistance in pancreatic cancer through glutaminolysis reprogramming. Co-author DOI 10.1038/s41419-026-09075-4↗
  5. Correction to: Functional biomarkers derived from computed tomography and magnetic resonance imaging differentiate PDAC subgroups and reveal gemcitabine‑induce… Co-author DOI 10.1007/s00259-025-07195-1↗
  6. Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses. Co-author DOI 10.1016/j.ccell.2025.09.003↗
  7. A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic cancer development. Co-author DOI 10.1038/s41467-025-56493-7↗
  8. c-Rel drives pancreatic cancer metastasis through fibronectin-integrin signaling-induced isolation stress resistance and EMT. Last author DOI 10.1186/s12943-025-02486-5↗
  9. DOTA-Based Plectin-1 Targeted Contrast Agent Enables Detection of Pancreatic Cancer in Human Tissue. Co-author DOI 10.1002/anie.202318485↗
  10. Dynamics and cytokinic regulation of immune cell infiltration in genetically engineered mouse models of pancreatic cancer dictate the sensitivity to immunother… Co-author DOI 10.1002/cac2.12496↗
  11. Hourglass, a compass navigating global and regional heterogeneity of pancreatic cancer†. Last author DOI 10.1002/path.6268↗
  12. Corrigendum to "Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a… Co-author DOI 10.1016/j.esmoop.2024.103463↗
  13. Corrigendum to "Prognostic and predictive value of CA 19-9 inlocally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a … Co-author DOI 10.1016/j.esmoop.2024.103705↗
  14. Pancreatic Cancer: Current Concepts, Trends, and Future Directions. Last author DOI 10.5152/tjg.2024.24544↗
  15. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic canc… Co-author DOI 10.1016/j.annonc.2022.09.161↗
  16. Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2021-325564↗
  17. Phenotype screens of murine pancreatic cancer identify a Tgf-α-Ccl2-paxillin axis driving human-like neural invasion. Co-author DOI 10.1172/jci166333↗
  18. Functional biomarkers derived from computed tomography and magnetic resonance imaging differentiate PDAC subgroups and reveal gemcitabine-induced hypo-vascular… Co-author DOI 10.1007/s00259-022-05930-6↗
  19. Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, mu… Co-author DOI 10.1016/j.esmoop.2022.100552↗
  20. Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2022.100815↗
  21. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic C… Co-author DOI 10.1200/jco.21.01604↗
  22. Deletion of pancreas-specific miR-216a reduces beta-cell mass and inhibits pancreatic cancer progression in mice. Co-author DOI 10.1016/j.xcrm.2021.100434↗
  23. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEO… Co-author DOI 10.1016/s2468-1253(20)30330-7↗
  24. Bcl3 Couples Cancer Stem Cell Enrichment With Pancreatic Cancer Molecular Subtypes. Last author DOI 10.1053/j.gastro.2021.03.051↗
  25. AGR2-Dependent Nuclear Import of RNA Polymerase II Constitutes a Specific Target of Pancreatic Ductal Adenocarcinoma in the Context of Wild-Type p53. Co-author DOI 10.1053/j.gastro.2021.07.030↗
  26. PALLD mutation in a European family conveys a stromal predisposition for familial pancreatic cancer. Co-author DOI 10.1172/jci.insight.141532↗
  27. Unraveling ERBB network dynamics upon betacellulin signaling in pancreatic ductal adenocarcinoma in mice. First author DOI 10.1002/1878-0261.12699↗
  28. Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine i… Co-author DOI 10.1016/j.annonc.2019.09.004↗
  29. Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel a… Co-author DOI 10.1016/j.annonc.2020.05.011↗
  30. Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.06.012↗
  31. Combating pancreatic cancer during its Rip Van Winkle sleep. Last author DOI 10.1038/s41422-020-0348-z↗
  32. Precision Therapy of Pancreatic Cancer: From Bench to Bedside. Last author DOI 10.1159/000509232↗
  33. Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology. Co-author DOI 10.1172/jci.insight.137809↗
  34. Subtypes of pancreatic stellate cells and distant metastasis of pancreatic ductal adenocarcinoma. Last author DOI 10.21037/atm.2020.03.136↗
  35. The Role of Autophagy in Pancreatic Cancer: From Bench to the Dark Bedside. Last author DOI 10.3390/cells9041063↗
  36. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. Co-author DOI 10.1056/nejmoa1903387↗
  37. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. Co-author DOI 10.1093/annonc/mdz406↗
  38. A machine learning model for the prediction of survival and tumor subtype in pancreatic ductal adenocarcinoma from preoperative diffusion-weighted imaging. Co-author DOI 10.1186/s41747-019-0119-0↗
  39. A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX … Co-author DOI 10.1371/journal.pone.0218642↗
  40. Chemotherapy of pancreatic cancer in patients with poor performance. First author DOI 10.21037/cco.2019.08.01↗
  41. Palliative chemotherapy in pancreatic cancer-treatment sequences. First author DOI 10.21037/tgh.2019.06.09↗
  42. NF-κB/Rel Transcription Factors in Pancreatic Cancer: Focusing on RelA, c-Rel, and RelB. Last author DOI 10.3390/cancers11070937↗
  43. A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer. Co-author DOI 10.7150/thno.29247↗
  44. Distinct Pathogenesis of Pancreatic Cancer Microvesicle-Associated Venous Thrombosis Identifies New Antithrombotic Targets In Vivo. Co-author DOI 10.1161/atvbaha.117.310262↗
  45. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, r… Co-author DOI 10.1186/s12885-018-5183-y↗
  46. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. Last author DOI 10.3389/fimmu.2018.01878↗
  47. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts. Last author DOI 10.1007/s40266-017-0453-y↗
  48. Early pancreatic cancer lesions suppress pain through CXCL12-mediated chemoattraction of Schwann cells. Co-author DOI 10.1073/pnas.1606909114↗
  49. ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage. Co-author DOI 10.1158/0008-5472.can-17-0634↗
  50. Activated Schwann cells in pancreatic cancer are linked to analgesia via suppression of spinal astroglia and microglia. Co-author DOI 10.1136/gutjnl-2015-309784↗

Closest collaborators

The 25 strongest of 250 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kıvanç Görgülü · 13 shared papers, 2017–2026 · strength 2.21
  2. Marina Lesina · 17 shared papers, 2011–2026 · strength 1.98
  3. Jens Thomas Siveke · 10 shared papers, 2019–2026 · strength 1.31
  4. Roland Michael Schmid · 14 shared papers, 2011–2025 · strength 1.26
  5. İhsan Ekin Demir · 10 shared papers, 2013–2026 · strength 1.22
  6. Thomas Jens Ettrich · 8 shared papers, 2018–2026 · strength 1.01
  7. Guralp Onur Ceyhan · 10 shared papers, 2013–2026 · strength 1.01
  8. Maximilian Reichert · 8 shared papers, 2013–2026 · strength 0.99
  9. Volker Kunzmann · 6 shared papers, 2021–2026 · strength 0.88
  10. Helmut Friess · 9 shared papers, 2016–2026 · strength 0.85
  11. Stefan Hubert Boeck · 6 shared papers, 2020–2026 · strength 0.83
  12. Roland Rad · 6 shared papers, 2020–2026 · strength 0.79
  13. Dietrich Alexander Ruess · 7 shared papers, 2017–2025 · strength 0.77
  14. Ingo Hartlapp · 5 shared papers, 2021–2026 · strength 0.76
  15. Frank Kullmann · 5 shared papers, 2021–2026 · strength 0.76
  16. Uwe M. Martens · 5 shared papers, 2021–2026 · strength 0.76
  17. Volker Heinemann · 5 shared papers, 2021–2026 · strength 0.76
  18. Rickmer Braren · 7 shared papers, 2019–2025 · strength 0.74
  19. Helmut Frieß · 7 shared papers, 2013–2025 · strength 0.71
  20. Uwe Pelzer · 6 shared papers, 2020–2024 · strength 0.71
  21. Carmen Mota Reyes · 5 shared papers, 2017–2026 · strength 0.69
  22. Brigitte Kimmel · 4 shared papers, 2022–2026 · strength 0.67
  23. Friedrich Anger · 4 shared papers, 2022–2026 · strength 0.67
  24. Wilko Weichert · 6 shared papers, 2019–2025 · strength 0.66
  25. Alexander Muckenhuber · 6 shared papers, 2019–2025 · strength 0.62

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.